Table 1. Clinical data for hepatitis C... | Rockefeller University Press

Table 1.

Clinical data for hepatitis C patients and healthy controls

N	IFN-a treatment (+)	IFN-a treatment (-)	Healthy controls
N	1,115	1,458	1,000
Sex and age (years)
Male	672	760	560
-<49	116	112	90
-50–59	132	107	95
-60–69	241	189	172
-70–79	152	269	161
->80	31	83	42
Female	443	698	440
-<49	62	96	63
-50–59	92	74	66
-60–69	166	174	134
-70–79	114	254	137
->80	9	100	40
Other chronic viral infections
HIV	5	3	0
HBV	5	17	0
-Chronic active infection	2	7	0
-Carrier	1	1	0
-Past infection	2	9	0
IL-28B SNP(rs8099917) genotype			N/A
TT (major)	817	890
TG (hetero)	234	248
GG (minor)	15	14
No Data	49	306
Duration of hepatitis (years)			N/A
<1	28	122
1–5	142	124
6–10	135	151
11–15	165	115
16–20	155	103
>20	208	143
Response to IFN-α treatment		N/A	N/A
SVR	771
Non-SVR	224
Discontinued	83
Other	10
No data	27

N	IFN-a treatment (+)	IFN-a treatment (-)	Healthy controls
N	1,115	1,458	1,000
Sex and age (years)
Male	672	760	560
-<49	116	112	90
-50–59	132	107	95
-60–69	241	189	172
-70–79	152	269	161
->80	31	83	42
Female	443	698	440
-<49	62	96	63
-50–59	92	74	66
-60–69	166	174	134
-70–79	114	254	137
->80	9	100	40
Other chronic viral infections
HIV	5	3	0
HBV	5	17	0
-Chronic active infection	2	7	0
-Carrier	1	1	0
-Past infection	2	9	0
IL-28B SNP(rs8099917) genotype			N/A
TT (major)	817	890
TG (hetero)	234	248
GG (minor)	15	14
No Data	49	306
Duration of hepatitis (years)			N/A
<1	28	122
1–5	142	124
6–10	135	151
11–15	165	115
16–20	155	103
>20	208	143
Response to IFN-α treatment		N/A	N/A
SVR	771
Non-SVR	224
Discontinued	83
Other	10
No data	27

N/A, not applicable.

Sharing Unavailable